Good morning. I am Donna Cochener, General Counsel and Corporate Secretary of Neurogene Inc., which we will refer to as Neurogene in this meeting. Welcome to our 2026 Annual Meeting of the Stockholders. I would like to introduce Dr. Rachel McMinn, Founder, Chief Executive Officer, and Executive Chair of the Board of Directors, who will call the meeting to order. Thank you, Donna. Good morning to you all. As the chair of this annual meeting of stockholders, I now call the meeting to order. With us here today are members of our board of directors and members of our senior management team. Our board of directors are Dr. Cory Freedland, our Lead Independent Director, Dr. Robert Baffi, Ms. Christine Mikail, Dr. Sarah Noonberg, Mr. Rohan Palekar, Mr. Keith Woods, and myself. In addition, we have with us Leah Grant of Broadridge Financial Solutions, Inc., Neurogene's proxy tabulator, representatives of Deloitte & Touche LLP, Neurogene's independent registered public accounting firm, and representatives from Gibson, Dunn & Crutcher LLP, Neurogene's outside legal counsel. Leah Grant has been appointed to act as the Inspector of Elections at this meeting by the Board of Directors. Our General Counsel, Ms. Cochener, will act as Secretary of the meeting and keep the minutes. I will now begin the formal agenda. Welcome to the 2026 annual meeting of stockholders of Neurogene. We will start with a review of the rules of conduct for the meeting, which I will ask Donna to review. Thank you, Rachel. In fairness to all stockholders attending the meeting and in the interest of having a fair, informative, orderly, and constructive meeting, the following procedures will apply. The business of the meeting will follow the order shown on the agenda, which has been made available to all guests at the meeting. In order to prevent possible confusion, we recommend that if you have previously voted by returning a proxy to us, you permit your proxy to stand. However, if you wish to revoke your proxy and vote during the meeting, or if you have not voted, or if you requested a legal proxy to attend the meeting, you will be given the opportunity to vote before the polls are closed. Only holders of record of common stock on April 7th, 2026, are entitled to participate in and vote at the meeting. Please note that under the advance notice provisions of our bylaws, proposals cannot be properly brought before this annual meeting unless they are submitted in accordance with those procedures set forth in our bylaws. Since we previously received no proposals from stockholders, in accordance with these advance notice provisions, no additional proposals may be submitted for consideration at this meeting. The chair of the meeting has the authority necessary to preside over the meeting and may make any and all determinations with respect to the conduct of the meeting and procedures to be followed during the meeting. You may submit any questions you have any time, and we will answer them once the business portion of the meeting has concluded. Thank you for your cooperation. If there is any stockholder present who has not returned a proxy or who desires to revoke a proxy and vote during the meeting, that stockholder should do so by clicking on the voting button on the web portal and following the instructions there. The polls opened at the beginning of the meeting, and we will close the polls on all matters immediately after the presentation and discussion of today's proposals. Let me remind all the stockholders present that if you have already sent in a proxy or voted by phone or through the Internet, there is no need to cast a ballot now unless you want to revoke your proxy or change your vote. The proxy holders will vote your shares as indicated on your proxy or as otherwise instructed. The proposals to be considered at this meeting, as set forth in Neurogene's definitive proxy statement, are as follows. One, to elect Robert Baffi and Rohan Palekar as Class III directors of Neurogene to hold office until the 2029 annual meeting of stockholders. Two, to approve by a non-binding advisory vote the compensation paid by Neurogene to its named executive officers. Three, to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of Neurogene for its fiscal year ending December 31st, 2026. Four, to hold a non-binding advisory vote on whether future non-binding advisory votes on the compensation paid by the company to its named executive officers should be held every one, two, or three years. I will now ask Donna to confirm that the notice and quorum requirements for this meeting have been met. Thank you, Rachel. I confirm that on or about April 16th, 2026, the notice of this meeting was mailed to all stockholders of record as of April 7th, 2026, the record date for this meeting. I have received an oath signed by the Inspector of Elections stating that she will faithfully execute with strict impartiality her duties, which will be filed with the minutes of this meeting. Only stockholders of record as of April 7th, 2026, are entitled to vote at this meeting. As of the close of business on the record date, the company had 15,615,786 shares of common stock outstanding and entitled to vote at this meeting. I am advised by the Inspector of Elections that more than 50% of shares of Neurogene common stock outstanding and entitled to vote at this meeting are represented in person or by proxy. Because holders of at least a majority of the shares entitled to vote at this meeting are present in person or represented by proxy, there is a quorum. I declare this meeting duly and lawfully convened for the purposes of transacting such business as may properly come before it. Thank you, Donna. As I mentioned earlier, any shares for which a proxy card was submitted prior to today's meeting will be voted in the manner directed on the proxy card. If you are a stockholder of record and plan to vote online at today's meeting, please vote now using the voting button on the web portal, as the polls will close in the next minute. The polls are now closed. I will now summarize the voting results based on proxy votes received prior to the meeting. Any votes submitted during this meeting will be included in the final report of the Inspector of Elections. The final voting results will also be included in a current report on Form 8-K to be filed with the Securities and Exchange Commission within four business days of today's meeting. According to the preliminary results, we have received votes and proxies sufficient to elect each of the director nominees to recommend a frequency for future advisory votes on compensation to be held every year and approve the other proposals voted on today. This concludes the business portion of the meeting, and the meeting is now adjourned. Comments or questions of general interest that you might have. Please note we will attempt to answer as many questions as time allows, but only questions that comply with the meeting rules of conduct will be addressed. No questions were submitted. Thank you for your time and attention today. The meeting is adjourned. This concludes the meeting. You may now disconnect.